Immunotherapy combo shows promise against tough rectal cancers
NCT ID NCT04130854
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding an immunotherapy drug called APX005M to standard treatment helps people with advanced rectal cancer achieve a complete response (no cancer left after treatment). 58 adults with stage II or III rectal cancer at high risk took part. The goal was to see if the combination leads to better outcomes than standard therapy alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
Dallas, Texas, 75390, United States
-
The University of Arizona Cancer Center
Tucson, Arizona, 85724, United States
-
Wake Forest Baptist Health Sciences
Winston-Salem, North Carolina, 27157, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can precision protons spare rectal cancer patients from harsh side effects?
- Could a single drug replace surgery for rectal cancer?
- Can adding chemo after radiation help older adults with rectal cancer avoid surgery?
- Can a common muscle relaxant make radiation deadlier for rectal cancer?
- Timing of chemo may boost rectal cancer remission
- Immunotherapy combo may boost rectal cancer treatment